Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 4.744
Filtrar
1.
Chem Pharm Bull (Tokyo) ; 72(3): 345-348, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38556262

RESUMO

Eperisone Hydrochloride was launched in Japan in 1983 and has been used to improve muscle tone and treat spastic paralysis (Originator: Eisai Co., Ltd.). However, its biochemical mechanism of action is unknown. SB Drug Discovery was used to evaluate purinergic P2X (P2X) receptor antagonism using fluorescence. In this study, we discovered that its target protein is the P2X7 receptor. Also, P2X receptor subtype selectivity was high. This finding demonstrates the (Eperisone-P2X7-pain linkage), the validity of P2X7 as a drug target, and the possibility of drug repositioning of Eperisone Hydrochloride.


Assuntos
Relaxantes Musculares Centrais , Propiofenonas , Relaxantes Musculares Centrais/farmacologia , Relaxantes Musculares Centrais/uso terapêutico , Antagonistas do Receptor Purinérgico P2X/farmacologia , Propiofenonas/farmacologia , Propiofenonas/uso terapêutico , Músculos
2.
J Pediatr Rehabil Med ; 17(1): 57-66, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38552121

RESUMO

PURPOSE: The use of intrathecal medications for the management of spasticity and various pain syndromes in the adult population has been previously reported. However, no evidence-based guidelines currently exist in the pediatric population. This case series presents patients (n = 8) with pediatric-onset disability who underwent placement of intrathecal baclofen pumps initially for management of severe spasticity. Despite titration of dose and use of oral analgesia, their uncontrolled pain persisted. Each patient was transitioned to a combination of baclofen and analgesic intrathecal therapy. The outcome in pain improvement and quality of life, as reported by patients and/or caregivers, were retrospectively reviewed. METHODS: Retrospective review of the background and decision-making process regarding transition to combination intrathecal therapy identified patient selection characteristics. Each patient and/or their caregivers completed a survey regarding improvements in pain, spasticity, function, and quality of life following initiation of combination intrathecal medications. RESULTS: Survey results revealed improvements in functional and pain assessments after initiation of combination baclofen and analgesic intrathecal medication. Patients and caregivers reported decreases in pain and oral spasticity medications. CONCLUSION: Use of pumps with antispasmodic and analgesic medication for combination intrathecal medication delivery should be considered in the management of patients with childhood-onset disabilities who have both severe spasticity and pain.


Assuntos
Baclofeno , Relaxantes Musculares Centrais , Adulto , Humanos , Criança , Baclofeno/uso terapêutico , Relaxantes Musculares Centrais/uso terapêutico , Estudos Retrospectivos , Qualidade de Vida , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/etiologia , Dor , Analgésicos/uso terapêutico , Bombas de Infusão Implantáveis
3.
Clin Ther ; 46(1): 74-78, 2024 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-37914584

RESUMO

A 65-year-old female with thoracic spinal stenosis and incomplete paraplegia underwent T11-T12 posterior thoracic interbody fusion. During postoperative rehabilitation, she experienced thigh pain, involuntary lower limb convulsions, and muscle fatigue. Despite being prescribed eperisone hydrochloride for relief, her muscle strength decreased after 14 doses. This adverse effect, not listed in the latest Chinese medication instructions, subsided 4 days after discontinuation. This case suggests eperisone hydrochloride potentially caused reversible muscle strength decline, highlighting its potential unsuitability for incomplete paraplegia patients due to possible further muscle strength reduction. We propose updating the medication instructions to alert clinicians to this risk.


Assuntos
Relaxantes Musculares Centrais , Propiofenonas , Humanos , Feminino , Idoso , Relaxantes Musculares Centrais/efeitos adversos , Propiofenonas/efeitos adversos , Força Muscular , Paraplegia/induzido quimicamente , Paraplegia/tratamento farmacológico
4.
Childs Nerv Syst ; 40(3): 895-903, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-37975904

RESUMO

Dystonia represents a significant source of disability in children. Generalized dystonia, which involves multiple body regions, leads to impaired mobility and motor function, resulting in substantial challenges in daily activities. Surgical treatments are used when medical treatments fail. Intrathecal baclofen (ITB) or deep brain stimulations (DBS) are the most employed surgical therapies. When these options are not feasible or ineffective, some authors have explored the use of intraventricular baclofen (IVB). In this report, we present four cases of pediatric patients with generalized dystonia who underwent treatment with IVB, resulting in notable improvements. To further explore the potential of this treatment modality, we conducted a comprehensive literature review. The findings from our study provide a comprehensive overview that can guide palliative management in similar cases.


Assuntos
Distonia , Distúrbios Distônicos , Relaxantes Musculares Centrais , Humanos , Criança , Baclofeno/uso terapêutico , Distonia/tratamento farmacológico , Relaxantes Musculares Centrais/uso terapêutico , Bombas de Infusão Implantáveis , Espasticidade Muscular
5.
J Am Geriatr Soc ; 72(1): 91-101, 2024 01.
Artigo em Inglês | MEDLINE | ID: mdl-37933734

RESUMO

BACKGROUND: The growth of oral muscle relaxant prescriptions among older adults in the United States is concerning due to the drugs' adverse sedative effects. Baclofen is a gamma-aminobutyric acid agonist muscle relaxant that is associated with encephalopathy. We characterized the risk of fall and fracture associated with oral baclofen against other muscle relaxants (tizanidine or cyclobenzaprine) in older adults. METHODS: We designed a new-user, active-comparator study using tertiary health system data from Geisinger Health, Pennsylvania (January 2005 through December 2018). Older adults (aged ≥65 years) newly treated with baclofen, tizanidine, or cyclobenzaprine were included. Propensity score-based inverse probability of treatment weighting (IPTW) was used to balance the treatment groups on 58 baseline characteristics. Fine-Gray competing risk regression was used to estimate the risk of fall and fracture. RESULTS: The study cohort comprised of 2205 new baclofen users, 1103 new tizanidine users, and 9708 new cyclobenzaprine users. During a median follow-up of 100 days, baclofen was associated with a higher risk of fall compared to tizanidine (IPTW incidence rate, 108.4 vs. 61.9 per 1000 person-years; subdistribution hazard ratio [SHR], 1.68 [95% CI, 1.20-2.36]). The risk of fall associated with baclofen was comparable to cyclobenzaprine (SHR, 1.17 [95% CI, 0.93-1.47]) with a median follow-up of 106 days. The risk of fracture was similar among patients treated with baclofen versus tizanidine (SHR, 0.85 [95% CI, 0.63-1.14]) or cyclobenzaprine (SHR, 0.85 [95% CI, 0.67-1.07]). CONCLUSIONS: The risk of fall associated with baclofen was greater than tizanidine, but not compared to cyclobenzaprine in older adults. The risk of fracture was comparable among the older users of baclofen, tizanidine, and cyclobenzaprine. Our findings may inform risk-benefit considerations in the increasingly common clinical encounters where oral muscle relaxants are prescribed.


Assuntos
Amitriptilina/análogos & derivados , Fraturas Ósseas , Relaxantes Musculares Centrais , Humanos , Idoso , Baclofeno/efeitos adversos , Relaxantes Musculares Centrais/efeitos adversos , Acidentes por Quedas , Estudos de Coortes , Fraturas Ósseas/induzido quimicamente
6.
J Neurosurg Pediatr ; 33(2): 179-184, 2024 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-38064708

RESUMO

OBJECTIVE: Intrathecal baclofen (ITB) is an effective treatment for refractory hypertonia in children. ITB has long been effective for the treatment of spasticity, and indications have naturally evolved to include dystonia and mixed pediatric movement disorders (PMDs). The established uses for ITB trials are insurance prerequisite, mixed tone, and family request. Despite agreement for ITB therapy by a multidisciplinary group of subspecialists in a complex PMD program, insurance companies often require an ITB trial be performed. A longitudinal cohort was identified to determine the safety and efficacy of ITB trials and to determine the utility of test dosing in this population. METHODS: Retrospective data analysis was performed for patients with hypertonia who underwent ITB bolus trials at the authors' institution between 2021 and 2023. Nonmodifiable risk factors and clinical variables were collected. RESULTS: Thirty-one patients (11 female) underwent 32 ITB trials. Of these patients, 67.7% had a diagnosis of mixed hypertonia, 32.3% pure spasticity, and 9.1% secondary dystonia. The mean age at test dose was 12.8 years, and 58.1% of patients were born premature. The mode Gross Motor Function Classification System score was 5. The mean difference in Barry-Albright Dystonia Scale (BADS) scores was -7.33 points (p = 0.01) at 2.5 hours postoperatively. The mean difference in upper-extremity modified Ashworth Scale (mAS) scores was -5.36 points (p = 0.003), and that for lower-extremity mAS scores was -6.61 (p < 0.001). In total, 21.9% of patients developed a post-dural puncture headache. Conversion to a permanent baclofen pump was performed in 22/32 (68.8%) patients. Of those who did not pursue pump placement, 1 patient had high surgical risk, 1 had an ineffective response, 1 had a bad reaction to the test dose and cited both regression and increased discomfort, and 2 declined despite an effective trial owing to family preferences. CONCLUSIONS: ITB trials require hospitalization in some form and carry risks of procedural complications. The decision to pursue a trial should be made on a case-by-case basis by clinicians and should not be determined by insurance companies. The complication rate of ITB trials is high, and a test dose is unnecessary in this fragile population.


Assuntos
Distonia , Distúrbios Distônicos , Relaxantes Musculares Centrais , Humanos , Feminino , Criança , Baclofeno , Estudos Retrospectivos , Distonia/tratamento farmacológico , Hipertonia Muscular/tratamento farmacológico , Espasticidade Muscular/etiologia , Espasticidade Muscular/complicações , Injeções Espinhais/efeitos adversos , Bombas de Infusão Implantáveis/efeitos adversos
7.
Spine Deform ; 12(2): 473-480, 2024 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-38006455

RESUMO

PURPOSE: To assess the complication risks associated with intrathecal baclofen (ITB) pumps in cerebral palsy (CP) patients undergoing posterior spinal fusion (PSF) and to determine if timing of pump implantation before or during PSF impacts the risk of complications. METHODS: A prospectively collected multicenter database was retrospectively reviewed to identify CP patients undergoing PSF from 2008 to 2023. Patients were divided into 2 cohorts: those with an ITB pump (ITB cohort) and those without (non-ITB cohort). The ITB cohort was further categorized by placement of the pump prior to or during PSF. Cohorts were then compared in terms of postoperative complications, perioperative complications, and need for revision surgery. RESULTS: Four hundred six patients (ITB n = 79 [53 prior to, 26 during PSF], non-ITB n = 326) were included in this analysis. At an average follow-up of 4.0 years (range 2-10 years), there were no significant differences between the ITB and non-ITB cohorts in the rate of perioperative complications (5.0% vs 6.5%, p = 0.80), revision surgeries (2.5% vs 4.6%, p = 0.54), or any complication type, regardless of whether pumps were placed prior to or during PSF, aside from longer surgical times in the latter group. CONCLUSION: Complication rates are similar for ITBs placed prior to and during PSF. Patients with spastic CP may safely be treated with ITB pumps without increased risks of complication or further reoperation/revision following PSF. LEVEL OF EVIDENCE: Level III.


Assuntos
Paralisia Cerebral , Relaxantes Musculares Centrais , Escoliose , Fusão Vertebral , Humanos , Baclofeno/efeitos adversos , Relaxantes Musculares Centrais/efeitos adversos , Estudos Retrospectivos , Fusão Vertebral/efeitos adversos , Bombas de Infusão Implantáveis/efeitos adversos , Escoliose/complicações , Paralisia Cerebral/tratamento farmacológico , Paralisia Cerebral/complicações
8.
Spinal Cord Ser Cases ; 9(1): 55, 2023 11 30.
Artigo em Inglês | MEDLINE | ID: mdl-38036498

RESUMO

INTRODUCTION: Intrathecal baclofen (ITB) therapy is an effective method of treating spasticity in persons with spasticity due to spinal cord injury (SCI), but complications are not rare and can include spinal fluid leaks, infection, and catheter/pump malfunction. CASE PRESENTATION: This study presents information related to an adult male patient with traumatic SCI and a history of two prior ITB pump pocket infections that required removal due to pump infection. The patient then developed skin erosion over the third pump, and the fluid around the pump grew methicillin-sensitive Staphylococcus aureus, diphtheroids, and Candida parapsilosis. The patient was initially treated with antibiotics and anti-fungal medication without removal of the ITB pump. The ITB pump was eventually removed 27 months later, and the fourth pump was implanted 10 months later. DISCUSSION: ITB pumps can be an effective treatment modality for spasticity in people with SCI; however, complications, including infection, can occur and require pump removal. This case illustrates a case of possible Candida colonization of the ITB pump, which was eventually removed.


Assuntos
Medula Cervical , Relaxantes Musculares Centrais , Traumatismos da Medula Espinal , Adulto , Humanos , Masculino , Baclofeno/uso terapêutico , Relaxantes Musculares Centrais/uso terapêutico , Candida parapsilosis , Bombas de Infusão Implantáveis/efeitos adversos , Traumatismos da Medula Espinal/complicações , Traumatismos da Medula Espinal/tratamento farmacológico , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/etiologia
9.
Int Rev Neurobiol ; 172: 79-99, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-37833019

RESUMO

RATIONALE: Spasticity develops in 80% of spinal cord injury cases and negatively affects the patents' quality of life. The most common method of surgical treatment for severe spasticity is a long-term intrathecal baclofen therapy (ITB). Long-term spinal cord stimulation is another possible treatment technique. This paper aims to evaluate the changes in quality of life for patients with spasticity who have been treated with neuromodulation (SCS or ITB) in 12 months after the surgery, as well to compare the changes in quality of life for patients who have been treated with spinal cord stimulation and those who received long-term intrathecal baclofen therapy. MATERIALS AND METHODS: The influence of spasticity, experienced by the patients with a spinal cord injury, on their quality of life was analyzed before the surgery and 12 months after it. The severity of the spinal cord damage was determined with the scale of the American Spinal Injury Association (ASIA); spasticity was evaluated with the modified Ashworth scale, Penn Spasm Frequency Scale; pain levels were determined with visual analogue scale (VAS), anxiety and depression levels - with HADS. Functional activity of the patients was evaluated with the help of the Functional Independence Measure (FIM). RESULTS: The treatment results for 33 patients (25 men and 8 women), aged from 18 to 62, are presented. After the trial stimulation, the patients were randomly assigned to either SCS or ITB group (18 and 15 people respectively). The decrease of spasticity in both experimental groups caused lower levels of pain, less functional dependency on other people, lower stress and depression rates and, as a consequence, better quality of life and social adaptation. The obtained results for SCS and ITB groups are statistically similar.


Assuntos
Relaxantes Musculares Centrais , Traumatismos da Medula Espinal , Masculino , Humanos , Feminino , Baclofeno/uso terapêutico , Qualidade de Vida , Espasticidade Muscular/terapia , Espasticidade Muscular/complicações , Traumatismos da Medula Espinal/complicações , Traumatismos da Medula Espinal/terapia , Dor
11.
Neurol Med Chir (Tokyo) ; 63(12): 535-541, 2023 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-37743509

RESUMO

Intrathecal baclofen (ITB) therapy effectively treats spasticity caused by brain or spinal cord lesions. However, only a few studies compare the course of treatment for different diseases. We investigated the change in daily dose of baclofen per year and its associated adverse events in patients presenting with the three most common etiologies at our institute: hereditary spastic paraplegia, cerebral palsy, and spinal cord injury. The ITB pumps were implanted from July 2007 to August 2019, with a mean follow-up period of 70 months. In patients with hereditary spastic paraplegia, baclofen dosage was reduced after eight years following ITB introduction, and the treatment was terminated in one patient owing to disease progression. In patients with cerebral palsy, the dosage increased gradually, and became constant in the 11th year. Patients with spinal cord injury gradually increased their baclofen dosage throughout the entire observation period. Severity and adverse event rates were higher in patients with cerebral palsy than in others. The degree and progression of spasticity varied depending on the causative disease. Understanding the characteristics and natural history of each disease is important when continuing ITB treatment.


Assuntos
Paralisia Cerebral , Relaxantes Musculares Centrais , Paraplegia Espástica Hereditária , Traumatismos da Medula Espinal , Humanos , Baclofeno/efeitos adversos , Paralisia Cerebral/complicações , Paralisia Cerebral/tratamento farmacológico , Relaxantes Musculares Centrais/efeitos adversos , Paraplegia Espástica Hereditária/complicações , Paraplegia Espástica Hereditária/tratamento farmacológico , Bombas de Infusão Implantáveis/efeitos adversos , Espasticidade Muscular/etiologia , Espasticidade Muscular/induzido quimicamente , Traumatismos da Medula Espinal/etiologia , Injeções Espinhais/efeitos adversos
12.
Childs Nerv Syst ; 39(10): 2877-2886, 2023 10.
Artigo em Inglês | MEDLINE | ID: mdl-37410128

RESUMO

PURPOSE: To review the neurosurgical treatments of children with movement disorders associated with cerebral palsy (CP) during the previous decades, up to the present day. METHODS: An extensive literature review was undertaken to identify important publications about this subject. My experience treating children with these disorders over the past three decades was included in the individual sections. RESULTS: Peripheral neurotomies have been developed for children with focal spasticity. For those with spastic paraparesis, selective lumbar rhizotomies were developed, and for those with spastic quadriparesis, intrathecal baclofen infusions were developed. Both effectively alleviate spasticity in the affected extremities. Generalized dystonia associated with CP has been treated with deep brain stimulation with mild improvement, but treatment with intrathecal baclofen and intraventricular baclofen improve those movements markedly. No effective treatment has been reported for children with athetoid CP. For those with choreiform CP, deep brain stimulation may be effective but intrathecal baclofen does not appear to be. CONCLUSION: Treatment of children with movement disorders associated with CP increased slowly in the 1970s and 1980s but accelerated rapidly in the 1990s with the introduction of lumbar dorsal rhizotomies and intrathecal baclofen. In the last 30 years, tens of thousands of children with spasticity and movement disorders associated with CP have been treated by pediatric neurosurgeons, and their care has become an integral component of current pediatric neurosurgical practice.


Assuntos
Paralisia Cerebral , Distonia , Transtornos dos Movimentos , Relaxantes Musculares Centrais , Criança , Humanos , Paralisia Cerebral/complicações , Paralisia Cerebral/terapia , Baclofeno/uso terapêutico , Espasticidade Muscular/etiologia , Espasticidade Muscular/terapia , Transtornos dos Movimentos/terapia , Transtornos dos Movimentos/complicações , Distonia/complicações
13.
Childs Nerv Syst ; 39(12): 3643-3645, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37458770

RESUMO

BACKGROUND AND IMPORTANCE: Intrathecal baclofen (ITB) pumps are an effective management tool for spasticity and dystonia. In the pediatric population, ITB complications including infection are common, and strategies to minimize their impact are important. Current standard of care for pump infection involves a wean of the ITB therapy followed by explantation of the hardware, which can be a three to 6-month process. CLINICAL PRESENTATION: We present a 20-year-old female who developed an pump pocket infection after revision. The pump was removed from the body but left connected. The pocket was debrided, thoroughly washed, and packed with multiple microbicidal agents. Nine days later, a new pump and proximal catheter was re-implanted without complications or interruption of medication administered intrathecally. One year later, the patient is doing well without any infectious problems. CONCLUSION: To our knowledge, this is the first report of an externalized pump and expedited reimplantation without a break in ITB therapy. Further studies are required in order to best characterize this technique as a potential alternative for infected baclofen pump pockets.


Assuntos
Baclofeno , Relaxantes Musculares Centrais , Feminino , Humanos , Adulto Jovem , Baclofeno/uso terapêutico , Bombas de Infusão Implantáveis , Relaxantes Musculares Centrais/uso terapêutico , Espasticidade Muscular/tratamento farmacológico
14.
Childs Nerv Syst ; 39(12): 3639-3642, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37515719

RESUMO

Limited therapies are available for severe cerebral palsy children (CP) with complex movement disorders, especially when both dystonia and spasticity are present. In this publication, we present the improvement of a child with severe CP after intracerebroventricular baclofen therapy. The treatment can impact not just the movement disorders but also on the quality of life of the child and caregivers. Global functional improvements can be observed on the 6-month follow-up.


Assuntos
Paralisia Cerebral , Transtornos dos Movimentos , Relaxantes Musculares Centrais , Criança , Humanos , Baclofeno , Paralisia Cerebral/complicações , Paralisia Cerebral/tratamento farmacológico , Qualidade de Vida , Bombas de Infusão Implantáveis , Espasticidade Muscular/tratamento farmacológico
15.
Int J Rehabil Res ; 46(3): 238-247, 2023 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-37345412

RESUMO

Our objective was to determine which pendulum test parameters are useful for detecting hypertonia in the knee muscles and assessing the group and individual responses to intrathecal baclofen (ITB) bolus injection among prospective pump recipients. We included 15 neurological patients with lower limb hypertonia (mainly spinal cord injury, n  = 7) and collected data the day before (baseline), and 2.5 and 5.0 h after the 50-µg ITB bolus injection. For comparison, data were collected in 15 healthy controls. The average over six test repetitions was obtained for the number of oscillations, swing time (SwingT), amplitudes of the first flexion and extension, maximum angular velocities of the first flexion (F1V) and extension (E1V), relaxation index, and damping coefficient (DampC). Across the patient group, all pendulum parameters indicated a significant decrease in hypertonia from baseline to postinjection (analysis of variance P  ≤ 0.004), except DampC. On the basis of the cutoffs from the receiver operating characteristic curve, all parameters were good or excellent discriminators of hypertonia in patients from normotonia in controls (area under the curve ≥0.85), with the highest sensitivity for SwingT and E1V (≥93%). Furthermore, all parameters except F1V revealed a significant shift from preinjection hypertonia to postinjection normotonia among patients (McNamar test P  ≤ 0.002, DampC excluded due to missing data), with the greatest responsiveness for E1V and relaxation index (≥73%). The results confirm the overall usefulness of pendulum test parameters in this patient population and indicate that some parameters are better at detecting hypertonia (SwingT, E1V) whereas others (E1V, relaxation index) are more responsive to the ITB injection.


Assuntos
Baclofeno , Relaxantes Musculares Centrais , Humanos , Baclofeno/uso terapêutico , Relaxantes Musculares Centrais/uso terapêutico , Estudos Prospectivos , Hipertonia Muscular/tratamento farmacológico , Extremidade Inferior , Espasticidade Muscular/tratamento farmacológico
16.
Int J Rehabil Res ; 46(3): 209-215, 2023 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-37345419

RESUMO

Since the first implantation in July 2001, the intrathecal baclofen (ITB) therapy for patients with generalized spasticity has been used in Slovenia for 20 years. The aim of this retrospective study was to evaluate the rates of different complications, especially if catheter-related complications were less frequent after the introduction of the coated catheter type in February 2013, and the potential correlation between higher baclofen doses and the incidence of complications. We retrospectively collected data from all patients in the registry during the period from 3 July 2001 to 31 December 2021. Among 138 patients (48 females), 120 patients had the first ITB system implanted at the University Medical Centre Ljubljana. Forty-three complications were reported in 38 patients (27%), with a total complication rate of 0.203/1000 days or 0.074/pump year. The most frequent was catheter-related (0.083/1000 days or 0.030/pump year), followed by skin-related (0.063/1000 days or 0.023/pump year) and pump-related complication (0.026/1000 days or 0.009/pump year). The incidence of catheter-related complications decreased significantly since the use of Ascenda type catheter: 14/7 complications per 88/147 implantations ( P  = 0.008). Patients with complications had a statistically significantly higher dose of baclofen: median 400 µg/24h vs. median 300 µg/24h ( P  = 0.016). Our retrospective analysis confirmed a significant decrease of catheter-related complications after the implementation of Ascenda type catheter in February 2013. Patients with a higher ITB dose had a statistically significantly higher incidence of complications. The total complication rate was a bit higher as previously reported in other studies, which is consistent with a long follow-up time.


Assuntos
Baclofeno , Relaxantes Musculares Centrais , Feminino , Humanos , Baclofeno/efeitos adversos , Estudos Retrospectivos , Relaxantes Musculares Centrais/efeitos adversos , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/etiologia , Eslovênia , Bombas de Infusão Implantáveis/efeitos adversos , Resultado do Tratamento , Injeções Espinhais/efeitos adversos , Complicações Pós-Operatórias
17.
J Med Case Rep ; 17(1): 239, 2023 Jun 11.
Artigo em Inglês | MEDLINE | ID: mdl-37301817

RESUMO

BACKGROUND: Intrathecal baclofen therapy can substantially improve symptoms in most patients with severe spasticity due to traumatic spinal cord injury, multiple sclerosis, or cerebral paresis. To the best of our knowledge, decompression surgeries at the intrathecal catheter insertion site in patients with a preexisting intrathecal pump for drug delivery have not been reported. CASE PRESENTATION: We report the case of a 61-year-old Japanese man with lumbar spinal stenosis who underwent intrathecal baclofen therapy. We performed decompression for lumbar spinal stenosis at the intrathecal catheter insertion site during intrathecal baclofen therapy. The yellow ligament was removed by partial resection of the lamina under a microscope to avoid damage to the intrathecal catheter. The dura mater was distended. No obvious cerebrospinal fluid leakage was observed. Postoperatively, lumbar spinal stenosis symptoms improved, and spasticity remained well controlled with intrathecal baclofen therapy. CONCLUSIONS: This is the first reported case of lumbar spinal stenosis decompression at an intrathecal catheter insertion site during intrathecal baclofen therapy. Preoperative preparation is necessary, as the intrathecal catheter may be replaced during surgery. We performed surgery without removing or replacing the intrathecal catheter, taking care not to damage the spinal cord by migrating the intrathecal catheter.


Assuntos
Relaxantes Musculares Centrais , Estenose Espinal , Masculino , Humanos , Pessoa de Meia-Idade , Baclofeno/efeitos adversos , Estenose Espinal/complicações , Estenose Espinal/cirurgia , Injeções Espinhais , Espasticidade Muscular/etiologia , Espasticidade Muscular/induzido quimicamente , Descompressão/efeitos adversos , Cateteres/efeitos adversos
18.
Am J Phys Med Rehabil ; 102(12): e160-e161, 2023 12 01.
Artigo em Inglês | MEDLINE | ID: mdl-37205746

RESUMO

ABSTRACT: We present the case of a posttraumatic C6 AIS A tetraplegic patient with spasticity treated with an intrathecal baclofen pump, who noticed a transient increase in his spasticity each time he used a digital tablet (Ipad) protected by a magnetic shell placed on his abdomen. Telemetry confirmed transient motor shutdown responsible for withdrawal symptoms each time the tablet was used. Symptoms resolved after the removal of the protective shell. Effects of magnetic fields like magnetic resonance imaging are known to stall the pump rotor, which recover at the end of magnetic resonance imaging. Other sources of magnetic fields like laptops or new smartphones with magnet charging technology may also interfere with implanted devices. We therefore recommend patients to avoid close contact of magnetic devices with the intrathecal baclofen pump. More robust studies are warranted to assess the effect of the new magnetic technologies on the function of intrathecal pumps.


Assuntos
Baclofeno , Relaxantes Musculares Centrais , Masculino , Humanos , Baclofeno/uso terapêutico , Bombas de Infusão Implantáveis , Espasticidade Muscular/tratamento farmacológico , Espasticidade Muscular/etiologia , Abdome , Campos Magnéticos , Relaxantes Musculares Centrais/uso terapêutico , Injeções Espinhais
19.
J Inherit Metab Dis ; 46(4): 543-553, 2023 07.
Artigo em Inglês | MEDLINE | ID: mdl-37254447

RESUMO

Glutaric aciduria type 1 (GA1) is an autosomal recessive disease frequently leading to dystonia. Deep brain stimulation (DBS), intrathecal baclofen (ITB), and intraventricular baclofen (IVB) are the current interventional treatment options for refractory dystonia. We performed a scoping review, individual patient data (IPD) analysis, and clinical trials review to summarize the existing literature on these interventions in this population, characterize outcomes, and suggest directions for future investigation. PubMed, Embase, and Scopus were searched following PRISMA guidelines. IPD were extracted from studies providing IPD for GA1 patients. ClinicalTrials.gov was reviewed. Of 139 articles, 7 studies with 10 patients were included. In study-level data, 2/4 (50.0%) DBS studies found no improvement in dystonia and 3/3 (100%) on baclofen found decreased dystonia and enteral medication regimen. In the IPD analysis, four studies with 5 patients (2 IVB, 2 DBS, 1 ITB) were included. The average percent reduction in dystonia was 29.9% ± 32.5% (median:18%, IQR:18%-29.2%). Function improved in 4 (80.0%) patients. All patients with reported changes in enteral dystonia-related medication regimen (3/3, 100%) reported reduction in medication usage. No patients (0%) had perioperative complications. Mean follow-up length was 14.8 ± 12.2 months. No interventional clinical trials were found. ITB, IVB, and DBS represent present neuromodulatory approaches for the treatment of GA1. ITB and IVB reduce dystonia, while DBS has a heterogeneous effect. ITB and IVB improved function and reduced enteral medication regimens. These findings must be viewed with caution considering limited data and a serious risk of bias. Further large-scale studies are necessary to determine indications for ITB, IVB, and DBS and elucidate treatment algorithms.


Assuntos
Estimulação Encefálica Profunda , Distonia , Distúrbios Distônicos , Relaxantes Musculares Centrais , Humanos , Baclofeno/uso terapêutico , Relaxantes Musculares Centrais/uso terapêutico , Espasticidade Muscular
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...